Search | Clinical Trials Finder

Conditions: Healthy Young Volunteers, Healthy Elderly Volunteers
Interventions: AZD3293, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza A
Interventions: Pimodivir 600 mg, Placebo, SOC Treatment; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 13 Years to 85 Years
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 28
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Fresno, California + 23 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Dimethyl Fumarate, Peginterferon Beta-1a, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Infections, Bacterial
Interventions: GSK2140944 capsule, GSK2140944 tablet, Itraconazole capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSVPreF3 OA investigational vaccine, FLU HD vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 65 Years and older
Enrollment: 1,029 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 46
States / cities: Birmingham, Alabama • Tempe, Arizona • Canoga Park, California + 41 more

Conditions: Stroke
Interventions: Mobile Service Robot Survey, Mobile Service Robot Survey for Patients; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Vaccines, Meningococcal Vaccines
Interventions: rLP2086 and Gardasil, rLP2086, Gardasil; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 11 Years to 17 Years
Enrollment: 2,499 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 87
States / cities: Daphne, Alabama • Chandler, Arizona • Jonesboro, Arkansas + 57 more

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 75 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Heart Failure, Coronary Disease, Diabetes Mellitus, Asthma, Hypertension, Hypercholesterolemia
Interventions: Community-based nurse care management; Other
Lead sponsor: Health Quality Partners; Other
Eligibility: 65 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2016
U.S. locations: 1
States / cities: Doylestown, Pennsylvania

Conditions: Myotonic Dystrophy
Interventions: SAR446268; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 10 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 4
States / cities: Gainesville, Florida • Tampa, Florida • New York, New York + 1 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Sildenafil citrate; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 15
States / cities: Phoenix, Arizona • Augusta, Georgia • Decatur, Georgia + 7 more

Conditions: Herpes Zoster, Herpes Zoster Vaccine
Interventions: Herpes Zoster vaccine GSK 1437173A, Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 865 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Golden, Colorado • Wichita, Kansas • Columbia, Maryland

Conditions: Mild Cognitive Impairment, Old Age; Debility
Interventions: Dual task perturbation training; Behavioral
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 55 Years and older
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Influenza
Interventions: MF59-eH1N1_f; Biological
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 2,719 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 20
States / cities: Miami, Florida • Lenexa, Kansas • Omaha, Nebraska + 16 more

Conditions: Acute Myeloid Leukemia
Interventions: Entinostat days 3, 10, 5AC, Entinostat days 10,17; Drug
Lead sponsor: Hetty Carraway; Other
Eligibility: 60 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 4
States / cities: New Haven, Connecticut • Baltimore, Maryland • Cleveland, Ohio

Conditions: Fabry Disease
Interventions: migalastat HCl 150 mg; Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 5
States / cities: Tampa, Florida • Atlanta, Georgia • Minneapolis, Minnesota + 2 more

Conditions: Respiratory Syncytial Virus Immunization
Interventions: RSV vaccine candiate formulation 1, RSV vaccine candidate formulation 2, Placebo; Biological · Other
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 865 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 25
States / cities: Huntsville, Alabama • Mesa, Arizona • Peoria, Arizona + 22 more

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 65 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 15
States / cities: San Diego, California • New Haven, Connecticut • Miami, Florida + 12 more

Conditions: Fibrodysplasia Ossificans Progressiva (FOP)
Interventions: Palovarotene; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 14 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania

Conditions: Congenital Adrenal Hyperplasia, 21-OHD
Interventions: Tildacerfont; Drug
Lead sponsor: Spruce Biosciences; Industry
Eligibility: 2 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 13
States / cities: Sacramento, California • San Diego, California • Chicago, Illinois + 10 more

Conditions: Cystic Fibrosis
Interventions: VX-809, Placebo, VX-770; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 26 more

Conditions: Staphylococcal Infections
Interventions: SA4Ag vaccine, Blood sample; Biological · Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 2
States / cities: Hollywood, Florida • South Miami, Florida

Conditions: Depressive Disorder
Interventions: saredutant (SR48968), placebo, escitalopram; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 60 Years to 64 Years
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Physical Fitness
Interventions: Equinox Personal Coaching; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 30 Years to 44 Years · Male only
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects

A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above

Mobile Service Robot for Task-Oriented Stroke Therapy: User Evaluations

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

Assessment of Primary Androgen Deprivation Therapy for Non-metastatic Prostate Cancer Among Elderly

Effect of a Community-based Nursing Intervention on Mortality in Chronically Ill Older Adults

A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1

To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.

Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older

Dual Task Perturbation Training for OAwMCI

Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults

A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)

Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.

A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

Evaluation of a Single Vaccination With a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years

An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder

Equinox Personal Coaching Versus Self-Directed Exercise